74 related articles for article (PubMed ID: 30405212)
21. Real-World Assessment of Renal and Bone Safety among Patients with HIV Infection Exposed to Tenofovir Disoproxil Fumarate-Containing Single-Tablet Regimens.
Nkhoma ET; Rosenblatt L; Myers J; Villasis-Keever A; Coumbis J
PLoS One; 2016; 11(12):e0166982. PubMed ID: 27941989
[TBL] [Abstract][Full Text] [Related]
22. Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients.
Quesada PR; Esteban LL; García JR; Sánchez RV; García TM; Alonso-Vega GG; Ferrández JS
Int J Clin Pharm; 2015 Oct; 37(5):865-72. PubMed ID: 26008219
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.
Palacios R; Hidalgo C; Ríos MJ; Rivero A; Muñoz L; Lozano F; Gutiérrez-Ravé V; Gálvez MC; del Arco A; Santos J
Eur J Clin Microbiol Infect Dis; 2009 Apr; 28(4):399-402. PubMed ID: 18841401
[TBL] [Abstract][Full Text] [Related]
24. Nonalbumin proteinuria predominates in biopsy-proven tenofovir nephrotoxicity.
Sise ME; Hirsch JS; Canetta PA; Herlitz L; Mohan S
AIDS; 2015 May; 29(8):941-6. PubMed ID: 25784440
[TBL] [Abstract][Full Text] [Related]
25. Tenofovir disoproxil fumarate-associated hypophosphatemia as determined by fractional excretion of filtered phosphate in HIV-infected patients.
Cheng CY; Chang SY; Lin MH; Ku SY; Sun NL; Cheng SH
J Infect Chemother; 2016 Nov; 22(11):744-747. PubMed ID: 27613487
[TBL] [Abstract][Full Text] [Related]
26. Discontinuation of tenofovir disoproxil fumarate for presumed renal adverse events in treatment-naïve HIV-1 patients: meta-analysis of randomized clinical studies.
Winston J; Chonchol M; Gallant J; Durr J; Canada RB; Liu H; Martin P; Patel K; Hindman J; Piontkowsky D
HIV Clin Trials; 2014; 15(6):231-45. PubMed ID: 25433663
[TBL] [Abstract][Full Text] [Related]
27. Tenofovir clearance is reduced in HIV-positive patients with subclinical tubular impairment.
Calcagno A; Cusato J; Marinaro L; Simiele M; Lucchiari M; Alcantarini C; Tettoni MC; Trentini L; Mengozzi G; D'Avolio A; Di Perri G; Bonora S
AIDS; 2016 Mar; 30(6):915-20. PubMed ID: 26636928
[TBL] [Abstract][Full Text] [Related]
28. Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study.
Sculier D; Gayet-Ageron A; Battegay M; Cavassini M; Fehr J; Hirzel C; Schmid P; Bernasconi E; Calmy A;
BMC Infect Dis; 2017 Jul; 17(1):476. PubMed ID: 28683720
[TBL] [Abstract][Full Text] [Related]
29. Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study.
Tsai MS; Chang SY; Lin SW; Kuo CH; Sun HY; Wu BR; Tang SY; Liu WC; Su YC; Hung CC; Chang SC
J Microbiol Immunol Infect; 2017 Dec; 50(6):789-797. PubMed ID: 26857335
[TBL] [Abstract][Full Text] [Related]
30. Long-term renal effects of tenofovir-disoproxil-fumarate in vertically HIV-infected children, adolescents, and young adults: a 132-month follow-up study.
Giacomet V; Nannini P; Vigano A; Erba P; Benincaso A; Bedogni G; Cattaneo D; Falvella FS; Zuccotti GV
Clin Drug Investig; 2015 Jul; 35(7):419-26. PubMed ID: 26013475
[TBL] [Abstract][Full Text] [Related]
31. Discontinuation of tenofovir disoproxil fumarate from initial ART regimens because of renal adverse events: An analysis of data from four multi-country clinical trials.
Ngongondo M; Ritz J; Hughes MD; Matoga M; Hosseinipour MC;
PLOS Glob Public Health; 2024; 4(1):e0002648. PubMed ID: 38175824
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
[TBL] [Abstract][Full Text] [Related]
33. Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir.
Gérard L; Chazallon C; Taburet AM; Girard PM; Aboulker JP; Piketty C
Antivir Ther; 2007; 12(1):31-9. PubMed ID: 17503745
[TBL] [Abstract][Full Text] [Related]
34. Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF.
Gathe J; Arribas JR; Van Lunzen J; Garner W; Speck RM; Bender R; Shreay S; Nguyen T
Patient; 2015 Oct; 8(5):445-54. PubMed ID: 26286337
[TBL] [Abstract][Full Text] [Related]
35. Bone mineral density decline according to renal tubular dysfunction and phosphaturia in tenofovir-exposed HIV-infected patients.
Casado JL; Santiuste C; Vazquez M; Bañón S; Rosillo M; Gomez A; Perez-Elías MJ; Caballero C; Rey JM; Moreno S
AIDS; 2016 Jun; 30(9):1423-31. PubMed ID: 26919733
[TBL] [Abstract][Full Text] [Related]
36. Nephrotoxicity Associated with Concomitant Use of Ledipasvir-Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection.
Bunnell KL; Vibhakar S; Glowacki RC; Gallagher MA; Osei AM; Huhn G
Pharmacotherapy; 2016 Sep; 36(9):e148-53. PubMed ID: 27459733
[TBL] [Abstract][Full Text] [Related]
37. Long-Term Follow-Up of Proteinuria and Estimated Glomerular Filtration Rate in HIV-Infected Patients with Tubular Proteinuria.
Peyriere H; Cournil A; Casanova ML; Badiou S; Cristol JP; Reynes J
PLoS One; 2015; 10(11):e0142491. PubMed ID: 26571117
[TBL] [Abstract][Full Text] [Related]
38. Renal outcomes in patients initiated on tenofovir disoproxil fumarate-based antiretroviral therapy at a community health centre in Malawi.
Chikwapulo B; Ngwira B; Sagno JB; Evans R
Int J STD AIDS; 2018 Jun; 29(7):650-657. PubMed ID: 29334883
[TBL] [Abstract][Full Text] [Related]
39. Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment.
Cressey TR; Avihingsanon A; Halue G; Leenasirimakul P; Sukrakanchana PO; Tawon Y; Jaisieng N; Jourdain G; Podany AT; Fletcher CV; Klinbuayaem V; Bowonwatanuwong C
Clin Infect Dis; 2015 Aug; 61(4):633-9. PubMed ID: 25921689
[TBL] [Abstract][Full Text] [Related]
40. Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice.
Costarelli S; Cozzi-Lepri A; Lapadula G; Bonora S; Madeddu G; Maggiolo F; Antinori A; Galli M; Di Perri G; Viale P; d'Arminio Monforte A; Gori A;
PLoS One; 2016; 11(10):e0160761. PubMed ID: 27716843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]